These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35152172)

  • 1. Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.
    Tang M; Lee CK; Lewis CR; Boyer M; Brown B; Schaffer A; Pearson SA; Simes RJ
    Lung Cancer; 2022 Apr; 166():40-48. PubMed ID: 35152172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
    Parikh RB; Min EJ; Wileyto EP; Riaz F; Gross CP; Cohen RB; Hubbard RA; Long Q; Mamtani R
    JAMA Oncol; 2021 Dec; 7(12):1843-1850. PubMed ID: 34734979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
    Mouritzen MT; Junker KF; Carus A; Ladekarl M; Meldgaard P; Nielsen AWM; Livbjerg A; Larsen JW; Skuladottir H; Kristiansen C; Wedervang K; Schytte T; Hansen KH; Østby AC; Frank MS; Lauritsen J; Sørensen JB; Langer SW; Persson GF; Andersen JL; Homann PH; Kristensen EB; Drivsholm LB; Bøgsted M; Christensen HS; Pøhl M; Bjørnhart B
    Acta Oncol; 2022 Apr; 61(4):409-416. PubMed ID: 35012430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
    Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
    Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.
    van Veelen A; Abtahi S; Souverein P; Driessen JHM; Klungel OH; Dingemans AC; van Geel R; de Vries F; Croes S
    Cancer Epidemiol; 2022 Jun; 78():102149. PubMed ID: 35429893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
    Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
    Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
    Griesinger F; Pérol M; Girard N; Durand-Zaleski I; Zacharias S; Bosquet L; Jänicke M; Quantin X; Groth A; Fleitz A; Calleja A; Patel S; Lacoin L; Daumont MJ; Penrod JR; Carroll R; Waldenberger D; Reynaud D; Thomas M; Chouaid C
    Lung Cancer; 2022 Oct; 172():65-74. PubMed ID: 36007281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
    Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Kim HW; Kim JS; Lee SH
    Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.